DIFFERENTIATED APPROACH TO THE SELECTION OF VITAMIN D PREPARATIONS FOR THE TREATMENT OF OSTEOPOROSIS


I.S. Dydykina (1), P.S. Kovalenko (1), A.A. Kovalenko (2)

1) FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova”, Moscow; 2) FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov” of RMH, Moscow
The article discusses the need for a differentiated approach to the selection of vitamin D preparations for the treatment of osteoporosis (OP). Data on the physiological role of vitamin D and the main causes of deficient states are presented. The features of the metabolism of native and active forms of vitamin D are described, including age-depending features. It is noted that alfacalcidol due to the absence of renal metabolism demonstrates greater clinical efficacy compared with native vitamin D in the treatment of various types of OP with a similar safety profile. Alfacalcidol as monotherapy is included in the clinical recommendations for the treatment of OP in contrast to native vitamin D, because it has demonstrated a more pronounced effect in terms of increasing bone mineral density, reducing the risk of falls, reducing the risk of fractures, and significantly reducing pain syndrome. The broad options in the selection of individual doses of Alfacalcidol (Alpha D3®-Teva) allows to choose the appropriate dosage for each patient with osteoporosis, taking into account the effectiveness and tolerability. This fact, along with the prevention of new fractures, elimination of pain syndrome and reducing the risk of falls contributes to improving the quality of life of patients of all ages.

About the Autors


Corresponding author: I.S. Dydykina – PhD, Leading Researcher at the Laboratory for the Evaluation of the Safety of Antirheumatic Drugs FSBIS SRIR n.a. V.A. Nasonova, Moscow; e-mail: dydykina_is@mail.ru


Similar Articles


Бионика Медиа